AUS
NZ
UK
CA
USA
IND
_07_14_2022_04_49_55_065075.jpg){kind=logo}
Highlights:
- AU$141.53 billion market cap company, CSL, has registered a 126% surge in its share price in last five years on the ASX.
- This healthcare stock has maintained a good dividend history and announced a dividend of AU$1.422 per share in April 2022.
- The company shared today that completion of proposed acquisition of Vifor is expected to take a little longer because of pending regulatory approvals.
Blue-chip darling on the ASX, CSL Limited (ASX:CSL) continuing its upward momentum, was seen trading 1.06% higher at AU$296.88 apiece at 11:43 PM AEST. With this, the shares have surged by more than 12% in one month, 7.24% in last six months, 5.78% in last one year and a whopping 126% in last five years. The 52-week high of CSL stands at AU$319.780. The market capitalisation of CSL is AU$141.53 billion.
At the given time, CSL shares were seen performing in line with its benchmark index, ASX 200 Health Care (INDEXASX:XHJ), which was 0.81% up at 42,673.20 points.
Talking about the broader market, the S&P/ASX200 is up today, gaining 26.30 points or 0.40% to 6,647.90. 7 of 11 sectors are higher along with the S&P/ASX 200 Index, Health Care being one of them.
What is up with the CSL’s share price?
Lately, it seems like CSL share’s movement is influenced by its sectoral performance since Health Care has been marking gains of late.
Recent updates by CSL
Image source: © Fahronii | Megapixl.com
Australian biopharmaceutical firm CSL provided the last update on 12 May 2022 regarding the proposed acquisition of Vifor Pharma. The company said that earlier it expected to close the transaction by June 2022, but now it expects the process to take a little longer, but did not mention the exact date or month.
Yesterday (13 July), Vifor Pharma shared via press release on its website that CSL has postponed the settlement of the transaction until 30 September 2022 as the company expects that required approvals will not be achieved before that.
On 14 December 2022, the company (CSL) announced that it will be buying Vifor for US$11.7 billion. Vifor is a pharmaceutical company specialising in iron deficiency and renal diseases.
According to the ASX announcement, Vifor would complement the existing therapeutic focus area of CSL.
CSL’s dividend history
In February 2022, the company announced a dividend of AU$1.422 per share, payable on 6 April 2022. The company declared a dividend despite reporting a 5% fall in the net profit after tax (NPAT) during the first half of 2022. During these six months, the earnings per share also dropped by 5% to US$3.77.
Before that, in September 2021, the company distributed an AU$1.589 dividend per share. In April 2021, the company declared a dividend of AU$1.349 and a dividend of AU$1.469 in October 2020.
Road ahead!
The company expects to deliver net profit after tax of US$2.15 billion to US$2.25 billion in the financial year 2022. The estimate includes around US$90 million to US$110 million required to fund the Vifor acquisition.
